Gilead games the system

QUICK READ: Those of us in the industry know that ANY information that comes from Gilead should be questioned. There was only one objective of these trails and that was to increase sales of Remdesivir.

This is a quote from a physician;

As someone who has conducted clinical trials, I am appalled at this optimism around Gilead’s drug Remdesivir. For one there is no control group. Further, (and this is not always true) the longer you treat someone with an effective drug the better you do, I.e in the absence of side effects of the drug, in this trial 5 days of treatment was better than 10 days. In the absence of data on how many patients were discharged within 14 days who did not receive Remdesivir how can one vouch for its effectiveness?. Maybe the same number would have been discharged irrespective of whether they took the drug. We don’t have that data. In general clinical trials are conducted at tertiary centers so they have more resources such as specialized doctors hence this data cannot be extrapolated to the general population. we all would wish for effective therapy but at first glance, this is far from it.

Wow

Another trial published in the medical journal The Lancet on Wednesday, first reported by the Financial Times last week, showed disappointing results. Conducted in China, the trial showed no statistically significant benefit for those taking remdesivir: patients taking the drug recovered on average in 21 days, compared with 23 days for those on a placebo.

There may have been a slight improvement if patients took the drug early. If they took the drug in the first 10 days after they developed symptoms, they recovered in an average of 18 days. Some analysts have supported that idea — it would make sense to take an antiviral before it spread enough to wreak havoc on certain parts of the body. But the authors warned this was still not statistically significant.

Most of the studies did not have a control arm or were, like the one described in the Journal of Medicine paper, based on data that was not collected as part of a trial. Gilead published results from its own study on Wednesday, which did not have a control group, comparing people who took the drug for five days with those who took it for 10 days, making it hard to draw broader conclusions. T

he bottom line: This near-constant back-and-forth over Remdesivir reinforces how strong the science and data need to be for any treatment, or for the world’s best hope: a vaccine.

Gilead is a prime example of everything that is wrong with pharma. Gilead doesn’t do much research and development itself. Instead, it has acquired firms that have done the heavy lifting and markets their successes. It acquired its blockbuster hepatitis C drug, Sovaldi, by paying $11 billion for the drug’s developer, Pharmasset, in 2011. By the way the person was working for the federal government at the time.

Now Gilead gets FDA emergency permission to use the drug for COVID-19 patients which means more money in their pockets. Really sad state of affairs.

Originally published at https://worldofdtcmarketing.com on April 30, 2020.

--

--

--

Marketing leader with over 20 years of online and offline award winning experience valued by clients

Love podcasts or audiobooks? Learn on the go with our new app.

Recommended from Medium

Be Careful With What You Eat

You might not want to read this if you’re eating right now.

Jobs Tried Exotic Treatments to Combat Cancer, Book Says

Protective Role of Vitamin C in NSAID-Induced GI injury

Did she hear voices from the Angel?

Acupuncture and Arthritis

Chair Cardio Workout with Triple Amputee.

I’m Fixing A Hole…In My Head

READ/DOWNLOAD%$ Trigger Point Therapy for Myofascial Pain: The Practice of Informed Touch FULL BOOK…

Get the Medium app

A button that says 'Download on the App Store', and if clicked it will lead you to the iOS App store
A button that says 'Get it on, Google Play', and if clicked it will lead you to the Google Play store
Richard A Meyer

Richard A Meyer

Marketing leader with over 20 years of online and offline award winning experience valued by clients

More from Medium

The Darkest of Mysteries

Ten reuses for Covid masks

Time To Sacrifice And Start Anew

The Internet Rears Its Ugly Head — Again!